Your browser doesn't support javascript.
loading
Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
Chappell, Nicole P; Miller, Caela R; Fielden, Aaron D; Barnett, Jason C.
Affiliation
  • Chappell NP; San Antonio Military Medical Center, Fort Sam Houston, TX nicpchappell@gmail.com.
  • Miller CR; San Antonio Military Medical Center, Fort Sam Houston, TX.
  • Fielden AD; San Antonio Military Medical Center, Fort Sam Houston, TX.
  • Barnett JC; San Antonio Military Medical Center, Fort Sam Houston, TX.
J Oncol Pract ; 12(7): e775-83, 2016 07.
Article in En | MEDLINE | ID: mdl-27246689
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Angiogenesis Inhibitors / Bevacizumab / Neoplasm Recurrence, Local Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Country/Region as subject: America do norte Language: En Journal: J Oncol Pract Year: 2016 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Angiogenesis Inhibitors / Bevacizumab / Neoplasm Recurrence, Local Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Female / Humans Country/Region as subject: America do norte Language: En Journal: J Oncol Pract Year: 2016 Document type: Article